302 related articles for article (PubMed ID: 23111865)
1. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
Villacampa F; Ruiz MA; Errando C; Arlandis S; Arumí D; Lizarraga I; Rejas J
Int Urogynecol J; 2013 Apr; 24(4):573-81. PubMed ID: 23111865
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumí D; Lizarraga I; Rejas J
Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
5. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
[TBL] [Abstract][Full Text] [Related]
6. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
7. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the 8-item overactive bladder questionnaire (OAB-v8) using item response theory.
Peterson AC; Sehgal A; Crump RT; Baverstock R; Sutherland JM; Carlson K
Neurourol Urodyn; 2018 Mar; 37(3):1095-1100. PubMed ID: 28976596
[TBL] [Abstract][Full Text] [Related]
9. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
10. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
[TBL] [Abstract][Full Text] [Related]
11. [Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder].
Errando-Smet C; Ruiz MA; Villacampa-Aubá F; Arlandis-Guzmán S; Rejas J; Ruiz L; García-Vargas M
Med Clin (Barc); 2013 Jan; 140(1):6-13. PubMed ID: 22257604
[TBL] [Abstract][Full Text] [Related]
12. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
[TBL] [Abstract][Full Text] [Related]
13. Should we use the shorter Thai-version quality of life and symptoms questionnaires in women with overactive bladder?
Bunyavejchevin S; Liao L; Lu SH; Choo MS; Rabbani KJ; Havanond P
J Obstet Gynaecol Res; 2015 Aug; 41(8):1260-5. PubMed ID: 26081949
[TBL] [Abstract][Full Text] [Related]
14. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
15. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
Rovner ES; Carlson KV; Deal AS; Nair KV; Oakkar EE; Park J; Gemmen E; Kristy RM; Gooch KL; Schermer CR
Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865
[TBL] [Abstract][Full Text] [Related]
16. Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.
Bunyavejchevin S
J Obstet Gynaecol Res; 2015 Jun; 41(6):957-61. PubMed ID: 25773663
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
[TBL] [Abstract][Full Text] [Related]
19. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?
Herschorn S; Kaplan SA; Sun F; Ntanios F
Urology; 2014 May; 83(5):1023-9. PubMed ID: 24582119
[TBL] [Abstract][Full Text] [Related]
20. Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.
Zinner N; Kobashi K; Koochaki P; Fix D; Egermark M
Neurourol Urodyn; 2011 Jan; 30(1):62-8. PubMed ID: 20860020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
